Posted by Michael Wonder on 03 Jul 2024
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection
27 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of osimertinib mesylate in the NHS in England.
For the time being, osimertinib mesylate is not recommended, within its marketing authorisation, for the adjuvant treatment of adults with stage 1b to 3a non‑small‑cell lung cancer after complete tumour resection whose tumours have an epidermal growth factor receptor exon 19 deletion or an exon 21 (L858R) substitution mutation.
